T he aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin and other lipid-altering therapies.
Introduction
Current therapeutic guidelines encourage early and aggressive treatment in individuals with type 2 diabetes to reduce the risk of cardiovascular disease, 1 which is a major cause of mortality in this population. 2 Type 2 diabetes patients with dyslipidaemia have a markedly increased risk of cardiovascular disease compared to non-diabetic patients with similar lipid levels. 3 Although elevated low-density lipoprotein (LDL) and decreased high-density lipoprotein (HDL) cholesterol levels have been shown to predict coronary artery disease in type 2 diabetes patients, 4 the concentrations of LDL cholesterol are often similar to or lower than those in non-diabetic patients. 5 Diabetic dyslipidaemia is characterised by reduced levels of HDL cholesterol, elevated triglycerides, and a high proportion of smaller and denser LDL particles. 6 This overall profile, as well as each lipid abnormality considered separately, correlates with increased cardiovascular disease risk in type 2 diabetes patients. 4, [7] [8] [9] In addition, the combination of high triglycerides with low HDL cholesterol levels can aggravate cardiovascular risk in these patients. 10 Linking improvements in each lipoprotein component to reduced cardiovascular risk has been challenging, particularly due to therapeutic intervention to improve multiple lipid changes. 11 The clinical rationale for managing diabetic dyslipidaemia with lipid-altering therapies stems from studies demonstrating clear reductions in cardiovascular events. 6 Treatment priorities are first to lower LDL cholesterol with statins and then to raise HDL cholesterol and reduce triglycerides with additional therapy. 6 Potential lipid-altering effects of oral antidiabetic agents, including those in the thiazolidinedione class, have also been evaluated in type 2 diabetes patients. Both rosiglita-zone and pioglitazone have demonstrated positive effects on glycaemic control, yet few published studies have evaluated their effects on blood lipid levels as primary outcome measures. With both drugs, HDL cholesterol levels have increased in monotherapy and combination studies. 12 In pioglitazone studies, LDL cholesterol levels usually remain unchanged and triglycerides decrease, whereas in rosiglitazone studies, these lipid changes are less consistent. 12 Pioglitazone also has been shown to reduce the number of LDL particles and to shift small, dense LDL particles to larger, less atherogenic particles, 13 which may provide additional benefits in the high-risk patient with type 2 diabetes and dyslipidaemia. Further effects on the diabetic dyslipidaemia profile have been observed in retrospective comparative studies [14] [15] [16] and in a prospective, randomised conversion study from troglitazone to pioglitazone or rosiglitazone. 17 Recently, a large, head-to-head, randomised controlled study comparing pioglitazone and rosiglitazone in patients naïve to treatment with statins or antidiabetic agents confirmed the differences in lipid response observed in earlier uncontrolled studies. [14] [15] [16] [17] The present study, designated as COMPLEMENT (to reflect its complementarity to the headto-head study done without statins 18 ), was designed to take into account the fact that most patients with type 2 diabetes meet the criteria for treatment with statins. 6 It was designed to determine whether lipid improvements conferred by pioglitazone in the head-to-head statin-naïve study 18 would be observed in patients who were switched from rosiglitazone to pioglitazone while maintaining constant statin and other lipid-altering therapies. The level of fasting triglycerides, the primary outcome, was measured along with total cholesterol, LDL cholesterol, HDL cholesterol, lipid particle diameters and concentrations, free fatty acids, apolipoproteins A-I and B, and high-sensitivity C-reactive protein (hs-CRP) levels.
Methods

Study subjects and procedures
This multicentre, single-arm open-label study was conducted at 53 centres in the US between November 2003 and August 2004: it consisted of screening for one week followed by open-label treatment for 17 weeks. Study subjects were 305 eligible patients with type 2 diabetes and dyslipidaemia, 18-70 of age years inclusive, who had received stable dosages of rosiglitazone and statin (with or without additional lipid-lowering therapy) for > 90 days. Enrolment haemoglobin A1c (HbA 1C ) was < 10.5% and mean fasting triglyceride levels were 5.17-25.86 mmmol/L (200-1,000 mg/dL). Exclusion criteria were: type 1 diabetes; gemfibrozil therapy within 90 days of screening; previous cancer history; alanine aminotransferase (ALT) level > 2.5 times the upper limit of normal, active liver disease or jaundice; serum creatinine levels > 2.0 mg/dL (male) or > 1.8 mg/dL (female); and anaemia.
At enrolment, blood samples were obtained for baseline laboratory analyses, rosiglitazone was stopped, and oral pioglitazone was initiated at 30 mg once daily. Investigators were allowed to increase the pioglitazone dosage to 45 mg/day at any time. Patients were expected to continue tak-ing their lipid-altering and oral antidiabetic therapies as before, using the same agents and dosage levels, including statins, nicotinic acid, fibrates (excluding gemfibrozil), bile acid-binding resins, and cholesterol absorption inhibitors. Patients returned for visits at weeks eight and 17, or underwent final visit procedures at the time of early discontinuation.
Eligible patients provided written informed consent before study-related procedures were initiated. Institutional review boards approved the informed consent form and study protocol. The study was conducted according to protocol, applicable US Food and Drug Administration Code of Federal Regulations, the Declaration of Helsinki, and the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice.
CRL Medinet, Inc. (Lenexa, KS) performed laboratory tests except lipid fractionation, which was performed by LipoScience, Inc., Raleigh, NC, with nuclear magnetic resonance (NMR) spectroscopy.
Statistical methods
The primary end point for this study was change in fasting triglycerides from baseline to final visit. Safety variables included adverse events, safety laboratory tests, vital signs, concomitant medications and compliance.
The sample size calculation was based on fasting triglycerides change from baseline at the final visit. At least 265 completing patients were determined necessary to detect a 0.64 mmol/L (25 mg/dL) difference using a 3.23 mmol/L (125 mg/dL) standard deviation, 90% power, and a 0.05 significance level. Assuming a 10% dropout rate, 300 patients was the enrolment target. Efficacy analyses were performed using the intention-to-treat population, defined as patients receiving at least one study medication dose. Missing values were imputed using the last observation carried forward. Efficacy variable changes from baseline were analysed using paired t-tests with baseline as a covariate. Shift tables summarised categorical end points as appropriate.
Patients receiving at least one study medication dose were included in the safety analysis. Treatment-emergent adverse events were defined as those for which onset occurred, severity worsened or intensity increased after patients receive study medication; events were coded using MedDRA, version 6.1 and summarised. Laboratory test and vital sign variables were summarised with descriptive statistics, change from baseline and shift tables.
No interim analyses were performed. Pre-specified exploratory analyses (Statistical Analysis Software package 8.1, SAS Institute, Inc., Cary, NC) included subgroup effects, including age, gender and race.
Results
Of 620 patients screened, 305 were enrolled from 53 investigative sites and received study drug. The study population (mean [SD] age: 57.6 [9.23] years) consisted of more men (63.9%) than women. The subjects were obese, with a body mass index (BMI) of 35.7 [6.84] kg/m 2 , and mostly Caucasian (87.9%). Another 8.5% of patients were Hispanic, 3.3% were black, and 2.6% were other races. Most patients (76.7%) had a history of hypertension. Other baseline clinical profiles included diabetic neuropathy (< 1/3 of patients), previous myocardial infarction (8.2%), peripheral vascular disease (5.2%), cerebrovascular accident (4.3%), or congestive heart failure (3.6%). Antidiabetic therapy included metformin (49.7%), insulin (31.5%), and sulfonylureas (34.7%). Atorvastatin and simvastatin were the most commonly used statins (52.2% and 29.5%, respectively). Fenofibrate and niacin were used by only 27 (8.9%) and eight (2.6%) patients, respectively.
At baseline, 38.8% of patients were receiving 4 mg and 54.4% were receiving 8 mg of rosiglitazone. At baseline conversion to pioglitazone, all but two patients started with 30 mg/day (two started with 15 mg/day, which was titrated to 30 mg/day by week eight). By last dose, 51.9% of patients were receiving 30 mg/day and 48.1% were receiving 45 mg/day of pioglitazone. Most enrolled patients (276 [90.5%]) completed treatment as far as week 17. Early discontinuation resulted from adverse events in 10 patients (3.3%), loss of follow-up in eight patients (2.6%), protocol violations in six (2.0%), voluntary withdrawal in four (1.3%), and an erroneously filled prescription in one (0.3%). Nearly all patients (99.8%) were compliant with study medication, which was assessed by comparing the number of tablets dispensed to the number of tablets returned at each study visit.
Glycaemic control
Glycaemic control remained stable after conversion to pioglitazone; at week 17, mean (SD) HbA 1C level did not differ significantly from baseline (table 1) .
Lipid profile
Baseline lipid concentrations and their mean changes at week 17 are listed in table 1; figure 1 depicts mean percent changes at week 17. After treatment conversion to pioglitazone, mean fasting triglycerides decreased significantly by week 17 by -1.68 mmol/L (-64.9 mg/dL) (95% CI -2.00 to -3.06 mmol/L [-77.6 to -52.3 mg/dL]; p<0.0001; n=280), and mean percent change from baseline was -15.2% (p<0.0001). This effect was greater in the subgroup of patients with baseline triglycerides above the study median of 6.89 mmol/L (266. 5 Lipid particulate subfraction analyses Lipid subfraction data for particle concentration and diameter as determined by NMR spectroscopy are shown in table 1 and figure 2. After conversion to pioglitazone, the total LDL particle concentration decreased: this was associated with an increase in large LDL particles and a decrease in small LDL particles. In addition, a statistically significant increase in mean LDL particle diameter was observed at week 17 (+0.23 nm; p<0.0001). Intermediate-density lipoprotein (IDL) particle concentration did not change significantly.
At week 17, total HDL concentration increased after pioglitazone treatment, and a shift in HDL subclass particle concentrations accompanied a slight decrease in mean HDL particle diameter. Total very low-density lipoprotein (VLDL) concentration decreased, which resulted from decreases in all VLDL particle subclasses without a significant change from baseline in mean VLDL particle diameter.
Apolipoproteins
Conversion from rosiglitazone to pioglitazone resulted in a significant (p<0.05) decrease in mean apolipoprotein B levels (0.026 g/L [-2.6 mg/dL]) at week 17 ( figure 1, table 1 ). Mean apolipoprotein A-I levels increased significantly at week 17 (0.097 g/L [+9.7 mg/dL]; p<0.001), corresponding with increases in total HDL particle concentration (figure 1, table 1).
Free fatty acids, hs-CRP and blood pressure
Other clinical parameters are shown in table 1. Free fatty acid levels at week 17 did not differ from baseline values. Similarly, hs-CRP levels at week 17 after conversion to pioglitazone did not differ significantly from baseline. Systolic and diastolic blood pressure at week 17 did not change from baseline. 
Subgroup analyses
Safety results
Overall, pioglitazone was safe and well tolerated in combination with statin therapy. Fewer than half of the patients (43.6%) had treatment-emergent adverse events; the majority of these were mild or moderate and not related to study drug. Fourteen patients (4.6%) had a severe adverse event (defined as an event that caused considerable interference with the subject's usual activities), and 58 (19.0%) had > 1 adverse events considered related to study drug. The most frequently reported adverse events were hyperglycaemia (3.3%), oedema (4.6%), hypoglycaemia (2.6%) and nasopharyngitis (2.3%). No myositis or rhabdomyolysis adverse events were reported. Seven patients (2.3%) had a cardiac event during this study; all of them improved or recovered. Four adverse events led to study drug discontinuation, including oedema in three patients and weight increase in one patient.
Nine patients reported a serious adverse event; no patient died during the study. Of four patients who had a serious cardiac adverse event, each had more than one substantial pre-existing cardiac risk factor in addition to dyslipidaemia. Two of these cardiac adverse events (acute myocardial infarction and congestive cardiac failure) led to study drug discontinuation. No serious adverse events related to glycaemic control, oedema, weight gain or hepatic dysfunction occurred.
Discussion
In this prospective, open-label conversion study, the baseline ORIGINAL ARTICLE lipid profile reflected the combined effects of the pre-existing rosiglitazone and statin therapies. The primary outcome measure, fasting triglycerides, was significantly reduced by 15% after 17 weeks of pioglitazone treatment after treatment conversion from rosiglitazone. This reduction is comparable with that seen in a small retrospective analysis in patients previously treated with troglitazone and statins 14 and is in line with differences seen in a randomised, controlled head-to-head study of pioglitazone and rosiglitazone without statins. 18 Total cholesterol levels showed significant reductions after pioglitazone treatment, consistent with previous uncontrolled and controlled head-to-head studies. 17, 18 No clinically important changes in LDL or HDL cholesterol levels were seen after switching medications. This lack of change is most likely due to low baseline LDL values, which reflect concurrent lipid-lowering treatment, and to high baseline HDL values, which reflect combined effects of previous treatment with statins and rosiglitazone.
Overall, conversion to pioglitazone treatment was safe and the numbers of weight gain or oedema adverse events were lower than those in previous reports, which may be attributed to prior thiazolidinedione use. 12, 18 After converting from rosiglitazone to pioglitazone, patients had a less atherogenic LDL particle profile, as well as improvements in VLDL and HDL subfractions, apolipoprotein B and apolipoprotein A-I. As anticipated from previous controlled studies, statistically significant improvements in LDL particle composition occurred, including an increase in average particle diameter, a decrease in small particle concentration, and an increase in large particle concentration. 17, 18 In a previous head-to-head trial, although both pioglitazone and rosiglitazone increased LDL particle diameter, the increase was greater with pioglitazone. 18 In the current study, in addition to the improved shift from smaller, denser to larger LDL particles with pioglitazone, the number of LDL particles decreased. Because statin doses remained stable from baseline, these effects can be attributed to pioglitazone alone. Improvements in LDL diameter and number, as seen in this trial, may have potential cardiovascular benefits. Previous studies have indicated that small, dense LDL particles and high VLDL particle concentrations have high atherogenic potential. 11, [19] [20] [21] As insulin resistance persists, the mean particle diameter of VLDL increases, and LDL and HDL particle diameters decrease. 11 In this study, converting from rosiglitazone to pioglitazone resulted in a positive reversal of these potential atherogenic trends in each lipid fraction, with the exception of no changes in IDL and benign HDL particle subfraction changes. The levels of VLDL and other triglyceride-containing components also decreased significantly, except the IDL subfraction. The VLDL and LDL subfraction and triglycerides findings are consistent with those in studies showing a correlation between increased plasma VLDL and triglycerides and smaller, denser LDL. 22 Apolipoprotein B, the protein moiety of LDL and VLDL, also was significantly decreased with reductions in LDL and VLDL particle concentrations, as expected. 23 Apolipoprotein B has been shown prospectively to be an independent risk factor for ischaemic heart disease. 24 Apolipoprotein A-I, the principal HDL component, increased significantly along with total HDL particle concentration. Some prospective evidence associates higher apolipoprotein A-I levels with cardiovascular benefits, but not independently of other lipids; 24 therefore, the clinical importance of the present apolipoprotein A-I findings is unclear. Also in this study, large HDL and small HDL particle concentrations increased significantly, whereas medium HDL particle concentrations decreased significantly. Though small HDL particles have been associated with co-morbid type 2 diabetes and cardiovascular disease, HDL particles of varying sizes may have cardioprotective benefits. 25 These study results are of relevance to most patients with type 2 diabetes who are taking rosiglitazone and lipid-lowering agents and who have triglycerides > 5.17 mmol/L (> 200 mg/dL). As determined with subgroup analyses, triglycerides and total cholesterol levels were reduced significantly in men and women, in Caucasian and non-Caucasian patients, and in all age groups independent of previous fibrate use. It is uncertain whether these results would apply to niacin, which was used infrequently, or to gemfibrozil, which was excluded due to potential drug interaction with statins and rosiglitazone. The study results warrant further analyses of lipo-protein and lipid particle changes in Hispanic, black and elderly patients.
The study had several limitations, including an openlabel and single-arm design. No washout period was used between rosiglitazone and pioglitazone doses; however, carryover effects from stable rosiglitazone doses, which are likely to have been lost within 12 weeks, would not be expected to result in the significant lipid and apolipoprotein improvements observed after conversion to pioglitazone. The average daily dose of rosiglitazone at baseline was 6.2 mg and of pioglitazone at week 17 was 37 mg. These averages approach the maximum dosage for each drug, and each resulted in similar glycaemic control. Without an active comparator, it could be argued that these lipid improvements could be the result of lifestyle modifications from participating in a clinical study. However, because patients served as their own controls, and no differences were seen between rosiglitazone and pioglitazone in effects on glycaemic control, free fatty acids, blood pressure or body weight changes, these facts strongly indicate that lipid improvements were caused by pioglitazone rather than by lifestyle changes. Another study limitation is lack of multiplicity testing, yet the study was well powered for the primary outcome, and improvements in triglycerides, total cholesterol, lipid particle number and diameter and apolipoproteins also were highly significant (p<0.001). Finally, we recognise that NMR spectroscopy as used in the current study can give different results for LDL size and subfractionation as compared to gradient gel electrophoresis, which is also commonly used for such measurements. 26 Nevertheless, since we used NMR spectroscopy in the same study subjects both before and after conversion from rosiglitazone to pioglitazone, the differences in the measured lipid parameters between the two drug treatments should be considered valid and reliable. At present, the mechanisms of the lipid differences between these two drugs are unknown.
In conclusion, results from the present study have implications for patients with type 2 diabetes and dyslipidaemia, and when combined with results of the previous randomised, head-to-head study 18 they reaffirm that pioglitazone as compared to rosiglitazone demonstrates improvements in overall lipid and lipid particle profiles. Furthermore, this study confirms these improvements independent of statin use. Although combinations of statins with nicotinic acid and fibrates are effective in modifying diabetic dyslipidaemia, these combinations can be associated with safety concerns and lipid targets may not always be reached. 6 Therefore, use of pioglitazone with statins offers a therapeutic option for diabetic dyslipidaemia, particularly for improving triglycerides and for potentially reducing cardiovascular disease risk. In this regard, the recently completed PROactive study has demonstrated that pioglitazone reduces the composite outcome of non-fatal myocardial infarction, stroke and allcause mortality in high-risk patients with type 2 diabetes and pre-existing macrovascular disease. 27 
